We aimed to characterize a potential role for phosphatidylinositol 3-kinase (PI3k) in leading to accelerated postoperative metastatic tumor growth. Background: PI3k enhances tumor cell survival in part by phosphorylating Akt and reducing apoptosis. Postoperatively, apoptosis is reduced within local recurrences and distant metastases. This reduction is associated with the phenomenon of accelerated postoperative tumor growth. Methods: Balb/c mice underwent a tail vein injection of 1 ϫ 10 5 metastatic murine mammary adenocarcinoma 4T1 cells. Animals were divided into the following treatment groups (n ϭ 10/group): group A, controls; group B, DMSO intraperitoneally (IP) daily from days 14 to 21; group C, IP LY294002 daily from days 14 to 21; group D, laparotomy only; group E, laparotomy followed by IP DMSO for 7 days; and group F, laparotomy followed by LY294002 IP for 7 days. All laparotomies were performed on day 14. Animals were killed at day 28. Metastatic tumor burden was assessed using the lung/body weight ratio and a histologic metastatic index. Mitotic counts and apoptotic indices were established using a combination of hematoxylin and eosin histology and TUNEL immunohistochemistry. A parallel survival study was performed, and PI3k activity was assessed using western blots for phospho-Akt. Results: Laparotomy was associated with increased systemic tumor burden (P ϭ 0.001). Postoperatively, LY294002 significantly attenuated metastatic tumor growth (P Ͻ 0.001). Effective PI3k inhibition was confirmed by demonstrating a reduced Akt phosphorylation. Moreover, PI3k inhibition led to reduced proliferation, increased apoptosis (P Ͻ 0.001), and enhanced postoperative survival (P Ͻ 0.001).
T here is a growing body of clinical and experimental evidence that tumor removal is associated with an acceleration in both local and systemic tumor growth. [1] [2] [3] [4] [5] [6] Indeed, several investigators have demonstrated that the surgical process itself creates a permissive environment in which the growth of residual neoplastic disease may be potentiated. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The potentiating effects of the perioperative environment are further (albeit indirectly) reflected in the differential effects of laparotomy and laparoscopy on recurrent tumor growth. 7, [13] [14] [15] [16] This is not a novel observation having been suggested separately by Rous, Paget and Tyzzer. [17] [18] [19] With an increase in the awareness of this phenomenon will come a search for therapeutic strategies that aim to protect against it. Such a search will require a greater understanding of the underlying extracellular, cellular, and intracellular events.
To date, most studies that have evaluated accelerated postoperative tumor growth have focused primarily on systemic tumor recurrence. 3, 4, 8, 10, 12, 20, 21 Many of these studies have shown that this postoperative phenomenon is associated with reduced apoptosis. 3, 4, 8, 10, 12, 20, 21 Recently, we developed a novel murine model that mimics the phenomenon of accelerated tumor growth within local recurrences. 5 In this model, accelerated local tumor recurrence is also associated with reduced apoptosis. 5 This model partly explains the accelerated manner in which local tumor recurrences often emerge and develop. As this model reproduces the properties of accelerated tumor growth following surgery, it serves as an excellent template to further study this phenomenon. 3, 5 Using this model, we demonstrated that accelerated tumor recurrence (at the local level) is associated with increased phosphoinositide-3 kinase (PI3k) activity. 5 PI3k is a tyrosine kinase that plays a central role in events such as apoptosis, proliferation, migration, and adhesion. [22] [23] [24] [25] [26] PI3k is associated with enhanced chemoresistance, particularly to potent chemotherapeutic agents such as TRAIL. Changes in PI3k subunit composition significantly enhance overall cell survival. Such are the pleiotropic effects of PI3k that it is often associated with tumor progression in general. [22] [23] [24] [25] [26] [27] [28] [29] The above findings refer to accelerated local recurrence following tumor cytoreduction. Previously, Pidgeon et al have demonstrated an acceleration in metastatic tumor growth following laparotomy. 4 Given that this has been repeated by others, we aimed to characterize the role of PI3k in accelerated postoperative metastatic tumor growth. 3, 10, 12, 20, 30 In particular, we aimed to determine if the targeting of PI3 kinase could protect against this phenomenon.
METHODS

Tumor Cell Line
All cell culture reagents were purchased from Biowhittaker Europe. A murine mammary adenocarcinoma cell line (4T1) was used (American Tissue Type and Culture, Rockville, MD). Cells were cultured to 80% confluency in RPMI-1640 supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 g/mL streptomycin sulfate, and 2 mM Lglutamine, in a humidified atmosphere of 5% CO 2 in air at 37°C. At 80% confluency, the cell culture was trypsinized using 0.25% trypsin-EDTA and washed 3 times in phosphatebuffered saline (PBS). Cells were then counted and resuspended in PBS at a concentration of 5 ϫ 10 5 /mL.
Animals
Weight matched female Balb/c (Harlen, UK) mice were used (age, 6 -8 weeks; weight, 25 Ϯ 2 g). Animals were housed in a licensed biomedical facility affiliated with Cork University Hospital. Following acclimation, animals were caged in groups of 6 in an air-conditioned room at 21°C with 50% relative humidity using a 12-hour light-dark cycle regimen. All animal-based experiments were performed by an authorized licensee according to guidelines as set out by the Ministry for Health in Ireland.
Animals were fasted prior to tumor inoculation. The tails were prepared with alcohol and the mice were sedated with a 0.5 mL of Hypnorm (Janssen, Buckinghamshire, UK). All animals received a tail vein injection of 200 L of 4T1 cells (0.5 ϫ 10 6 cells/mouse), prepared as above. The animals were warmed until recovered from sedation.
Animals were divided into the following groups (n ϭ 10/group): group A were control animals that received no treatment; group B received DMSO (Sigma) (35%) intraperitoneally (IP) daily from days 14 to 21; group C received IP LY294002 (Sigma) (100 g/day in 35% DMSO) daily from days 14 to 21; group D underwent laparotomy only; group E underwent laparotomy and received IP DMSO (35%) postoperatively for 7 days; and group F underwent laparotomy and received LY294002 (100 g/day) IP for 7 days postoperatively. As DMSO, the vehicle for LY294002, is also a chemotherapeutic agent, it was necessary to characterize the perioperative effects of DMSO (hence the inclusion of group B, DMSO alone). Anesthetic induction and maintenance were achieved using halothane (Rhone-Merieux-Harlow, UK). A midline laparotomy was performed and the peritoneum was incised longitudinally. Peritoneal contents were then exposed for 30 minutes during which the small bowel underwent exteriorization and manipulation. Next, a brief peritoneal washout was performed using normal saline. The laparotomy was closed in 2 layers using nonabsorbable sutures, and all animals were recovered on a heated blanket.
Survival Study
The above experiment was repeated to determine whether the administration of LY294002 was associated with a survival benefit following laparotomy. In this experiment, group A mice underwent a laparotomy only, group B mice underwent a laparotomy and received DMSO as described above, and group C underwent a laparotomy and received LY294002 as described above. A Kaplan-Meier log-rank analysis was used to compare survival levels between groups.
Metastatic Burden
Metastatic burden was first evaluated by calculating the lung/body weight ratio for each animal, as previously described. 30, 31 All evaluations were performed in a blinded manner. The lungs were retrieved, formalin-fixed, and wax embedded prior to sectioning at a thickness of 8 m. Next, sections were stained with hematoxylin and eosin. As differences in weights (between groups) may confound an evaluation of the lung/body weight ratio, metastatic tumor burden was further assessed by calculating the mean number of metastases per 10 low power fields for each animal. This generated a histologic index of metastatic tumor burden. This represented a direct evaluation of metastatic tumor growth.
Mitosis
Mitotic cells were identified morphologically and a mitotic index was established using the mean number of mitotic cells per 10 high power fields. Both mitotic and apoptotic indices (see below) were established by 2 independent observers who were blinded to the nature of the groups being assessed.
Apoptosis
A terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP-digoxigenin end labeling (TUNEL) apoptotic assay was performed as previously described. 32 Biopsy specimens were immerse fixed in buffered formalin (4% vol/vol) for 12 hours. These were embedded in paraffin wax and 7-m sections taken. Pretreatment was by microwave irradiation at 350 watts for 5 minutes in citrate buffer (0.01 M citrate buffer at pH 6.0). Rapid cooling was achieved by immersing the slides in PBS at room temperature. Preliminary comparative studies with Proteinase K showed that antigen retrieval was better using the microwave irradiation technique. Specimens were exposed for 1 hour, at room temperature in a humidity chamber, to the TUNEL mixture. This contained equilibration buffer (98 L), biotinylated nucleotide mix (1 L), and TdT (1 L) (Promega;Dead-End Apoptosis kit). TdT was omitted from the TUNEL labeling mixture in the TUNEL negative controls. Positive controls were obtained by pretreating with Dnase prior to incubation with the TUNEL labeling mixture. Endogenous peroxidases were blocked by immersing the slides in 0.3% hydrogen peroxide for 3 minutes at room temperature. Sections were then incubated with streptavidin horseradish peroxidase at 1:500 in PBS for 30 
Western Blot Analysis
Lungs were harvested as described above. Pulmonary metastases were macrodissected under a Leica microscope and then lysed using lysis buffer (1% Triton X-100, 20 mM Tris, 137 mM NaCL, 1 mM PMSF, 2 mM Na 3 VO 4 , 10 g/mL leupeptin, 2 g/mL aprotinin). Protein concentrations were determined using a RIPA assay. Proteins were then denatured at 95°C for 10 minutes in loading buffer containing 60 mM Tris, 2.5% SDS, 10% glycerol, 5% mercaptoethanol, and 0.01% bromophenol blue. Aliquots that contained equal protein amounts were loaded onto SDS-polyacrylamide gels and transblotted onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Following a 2-hour blocking period in TBS containing 0.1% Tween-20 and 6% nonfat milk, membranes were subsequently probed overnight at 4°C with the appropriate primary antibodies. Blots were then further incubated for 1 hour with either horseradish peroxidase-conjugated anti-rabbit IgG (Promega) or anti-goat IgG (Santa Cruz, Biotechnology) and then developed using an enhanced chemiluminescence detection system according to the manufacturers' instructions. The primary antibody used was rabbit antihuman phospho Akt (Ser 473)(Cell Signaling: 9271).
Statistical Analysis
All statistical analysis was performed using Sigma-Stat, and P Ͻ 0.05 was taken as significant.
RESULTS
Animal Weights
Animals were weight matched prior to commencement of the study. There were no significant differences in animal weights between groups at the termination of the study.
Lung/Body Weight Ratio
The lung/body weight ratio was significantly increased in animals that underwent a laparotomy compared with controls (P ϭ 0.001, Fig. 1A ). However, this effect was significantly attenuated in animals that received LY294002 postoperatively (P Ͻ 0.001, Fig. 1A ). Pulmonary metastatic tumor burden was demonstrably increased in animals that underwent laparotomy compared with control animals (ie, those that did not undergo laparotomy) ( Fig. 1B, C) . The lung/body weight ratio was also decreased in mice that did not undergo a laparotomy but received LY294002 (group C, Fig. 1A ). However, this reduction was not statistically significant. In animals that underwent a laparotomy and received LY294002 postoperatively, the lung/body weight ratio was reduced to levels that were less than those seen on animals that did not undergo laparotomy. Although this reduction was not significant, it was a trend that was repeatedly observed.
Hence, LY294004 abrogates the effects of laparotomy on metastasis growth and also appears to reduce spontaneous tumor growth. None of these effects can be attributed to DMSO as DSMO alone did not significantly reduce metastasis formation (Fig. 1A ).
Pulmonary Metastases
The lung/body weight ratio is an indirect measure of pulmonary metastatic tumor burden. Measuring the number of pulmonary metastasis is a more direct measure and hence may more accurately reflect tumor burden. The mean number of pulmonary metastases was almost doubled in mice following laparotomy (P ϭ 0.025, Fig. 1D ). LY294002 administration, during the immediate postoperative interval, completely attenuated this effect (P ϭ 0.002) and reduced metastatic burden to values less than those seen in control mice (ie, those that did not undergo laparotomy) (Fig. 1D ). DMSO administration was associated with a slight but insignificant reduction in the mean number of metastatic nodules (Fig.  1D ). This alone could not account for the effects of LY294002 administration during the postoperative interval.
TUNEL Apoptotic Index
In the past, several studies have demonstrated reduced levels of apoptosis in metastases following the process of either tumor removal or laparotomy. 3, 4, 8, 10, 12, 20, 21, 33, 34 In the present study, apoptosis levels were again significantly reduced within pulmonary metastases following laparotomy ( Fig. 2A -C: P ϭ 0.021). TUNEL-positive apoptotic cells were readily identified in counterstained sections (Fig. 2B,  C) . Apoptotic cells were demonstrably fewer in pulmonary metastases in animals that underwent a laparotomy (Fig. 2B,  C) . However, the administration of LY294002 not only restored apoptosis levels but also increased apoptosis to levels greater than those seen control animals (P Ͻ 0.001, Fig. 2A ). DMSO administration was also associated with a slight but insignificant increase in apoptosis.
Mitotic Index
When pulmonary metastases were evaluated for cell proliferation, this was seen to increase significantly following laparotomy (P Ͻ 0.001, Fig. 2D ). Following laparotomy, cell proliferation increased to more than double levels seen in control animals (Fig. 2D ). While LY294002 administration led to a reduction in mitotic figures, this was not statistically significant (P ϭ 0.056, Fig. 2D ).
Mitotic/Apoptotic Ratio
The net mitosis/apoptosis ratio is a critical determinant of overall growth. In the present study, this was found to markedly increase following laparotomy (P Ͻ 0.001, Fig.  2E ). This increase reflects the cumulative effects of increased cell proliferation and reduced apoptosis, following laparotomy. In animals that received postoperative LY294002, the mitosis/apoptosis ratio was significantly reduced (P ϭ 0.003) and approached levels that were similar to those seen in animals that did not undergo laparotomy. 
Survival
Survival was compared for animals that underwent laparotomy alone, and for those that underwent laparotomy and received either LY294004 or DMSO postoperatively. Following laparotomy, most animals died of intrathoracic hemorrhage during the third postoperative week (Fig. 3A) . A significant improvement in survival was evident when animals received LY294002 postoperatively (P Ͻ 0.001). This was related to LY294002 specifically, as survival was largely unchanged in animals that received DMSO alone (P ϭ 0.6) (Fig. 3A) .
Akt Phosphorylation
Akt represents a substrate for PI3k. 22, 23, 28 Once activated, PI3 kinase phosphorylates Akt. Phosphorylated Akt leads to reduced apoptosis, increased cell survival, and proliferation. 22, 23, 25, 28, [35] [36] [37] The targeting of PI3 kinase with LY294002, if successful, should lead to a reduction in Akt phosphorylation. To determine this in vivo, we macrodis-sected pulmonary metastases and found that whole-cell Akt phosphorylation was increased following laparotomy (Fig.  3B ). LY294002 was associated with a significant reduction in Akt phosphorylation following laparotomy (Fig. 3B ). While LY294002 reduced Akt phosphorylation, phosphor-Akt levels remained increased over those seen in control animals (Fig. 3B) .
Toxicity
Previous studies have demonstrated that LY294002 administration may be associated with dermal toxicity, manifesting in a skin rash. 38, 39 No such overt toxicity was observed in the present study. In addition, in animals that received LY294002, all wounds remained intact with no evidence of breakdown.
DISCUSSION
Tumor removal remains the single most important treatment modality, in the management of solid malignancy. FIGURE 1. Bar charts summarizing pulmonary metastatic burden as indicated by the lung/body weight ratio (A) and the histologic metastatic index (D). Group A were control animals that received no treatment, group B received DMSO (35%) intraperitoneally (IP) daily from days 14 to 21, group C received IP LY294002 (100 g/day in 35% DMSO) daily from days 14 to 21 (Sigma), group D underwent laparotomy only, group E underwent laparotomy and received IP DMSO (35%) postoperatively for 7 days, and group F underwent laparotomy and received LY294002 (100 g/ day) IP for 7 days postoperatively (n ϭ 10 animals per group). B, Photograph of lungs in a control Balb/c mouse (ie, no laparotomy) killed 4 weeks following the onset of the study. Normal lung parenchyma is evident surrounding pulmonary metastases. C, Photograph of lungs excised from a Balb/c mouse that underwent laparotomy and was killed 2 weeks following the latter. No normal parenchyma is evident.
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Targeting Pi3K and Perioperative Tumor Growth However, several studies indicate that the process of tumor removal (ie, the surgical process) may potentiate the growth of residual neoplastic disease. 1-6,10,11,15,40 -42 While this may appear at first novel, it is indeed not, and partly has origins in the observations of Paget himself. 19 Paget noted that outcome for patients who underwent tumor removal is not always as good as outcome in patients managed expectantly. 19 Early during the twentieth century, Tyzzer et al, 17 Jones and Rous, 18 and O'Reilly et al 8 separately demonstrated that neoplastic cells exhibit a predilection for sites of tissue trauma. More recently, it has been shown that there is a temporal advancement in the death specific hazard ratio for women who undergo mastectomy versus those managed expectantly. 40, 41 These findings prompted an ongoing search for potential mediators of this phenomenon. Several candidate mediators have emerged, including endostatin, angiostatin, lipopolysaccharide, TNF-␣, IL6, TGF-␤, PDGF, VEGF, and others. 6, 42, 43 Surprisingly, no studies to date have addressed the intracellular basis for the systemic aspect of this phenomenon. PI3k is strongly implicated in neoplasia. 5, 22, 25, 26, 29, 38, 39, 44 Recently, we purified epithelia from primary and recurrent tumors and demonstrated that the accelerated manner in which locally recurrent tumors develop is strongly associated with reduced levels of apoptosis. 5 Unfortunately, however, it is systemic disease that is the principal cause of mortality associated with solid tumors. This is compounded by the fact that the surgical process, as described above, can potentiate metastatic tumor growth. Given our previous findings regarding PI3k, we aimed to characterize the role of this pathway in accelerated systemic tumor growth following laparotomy.
The findings presented here first confirmed previous observations that, following laparotomy, pulmonary meta-FIGURE 2. Bar charts summarizing the apoptotic (A), mitotic (D), and mitotic/apoptotic (E) indices for groups A to F (see Fig. 1 for description of groups). B, Photomicrograph (original magnification ϫ40) demonstrating TUNEL-positive (and hence apoptotic) cells in a metastasis present in the lungs shown in Figure 1B (ie, no laparotomy). C, Photomicrograph (original magnification ϫ40) demonstrating reduced numbers of TUNEL-positive cells in a metastasis present in the lungs shown in Figure 1C (ie, following laparotomy). static tumor growth is increased. It remains to be determined if this results from increased spontaneous metastasis formation or from the more rapid growth of metastases already present. The targeting of PI3k not only reduced pulmonary metastatic burden but reduced it to levels that were less than those seen in control animals (ie, those that did not undergo laparotomy and received no adjuvant treatment). This pattern was repeated when pulmonary metastatic burden was evaluated more directly using an histologic index. Hence, the targeting of PI3k completely protected against the potentiating effects of laparotomy and also appeared to reduce spontaneous metastatic tumor growth. These findings underscore a major role for the PI3k/Akt pathway in both spontaneous metastasis formation and, also, in accelerated metastatic growth following laparotomy.
With the exception of the treatment of hepatic metastases, laparotomy is an uncommon event in the management of breast cancer. The model described above, ie, laparotomy in the presence of a murine mammary adenocarcinoma cell line, is well described in the literature. 4, 6, 31 However, this phenomenon had also been described for a variety of other murine models involving a range of cell types. 14, 15, 42, [45] [46] [47] [48] Previously, we have demonstrated that the phenomenon of accelerated perioperative tumor growth occurs irrespective of the cell line origin (ie, murine or human), irrespective of murine immune status (ie, immunocompromised or not), and is also seen in human colonic explants. 5 Hence, this is a generalized phenomenon in the experimental setting.
Postoperative LY294002 significantly enhanced apoptosis levels within pulmonary metastases. This was associated with a reduction, albeit insignificant, in cell proliferation. Both these effects were associated with reduced levels of Akt phosphorylation as well as with significantly enhanced survival. When these observations are taken in the context of our previous findings, they further strengthen the suggestion that PI3k/Akt plays a major role in regulating tumor recurrence at the systemic level.
Based on the above findings, the following model may be proposed as partly explaining some of the intracellular events that underpin accelerated tumor growth following surgery. Extracellular mediators increase following tumor removal, or laparotomy, and lead to increased intracellular PI3k activity. These mediators remain to be identified. The activation of PI3k in turn leads to increased Akt phosphorylation. The result of the latter is to reduce overall levels of apoptosis. This phenotype is reversed when Pi3k is inhibited with LY294002. As demonstrated in this manuscript, the increases seen in apoptosis (following the targeting of Pi3k) are significant. These findings thus point to a major role for Pi3k in regulating postoperative apoptosis within residual neoplasia. Increased activation of Pi3k thus leads to an increase in the mitosis/apoptosis ratio (by reducing apoptosis), a critical determinant of overall tumor growth. This, in turn, manifests in increased metastatic tumor burden. Finally, these effects may be attenuated by reversing the antiapoptotic phenotype through the targeting of Pi3k.
It may be suggested that the definitive role of PI3k, during the perioperative period, could be established using knockout mice. This approach is complicated by the fact that class Ia Pi3k is comprised of regulatory (p85␣) and catalytic (p110␥) subunits, the relative expression of which determines overall activity. 36, 49 However, a p110␥ Ϫ/Ϫ mouse is currently unavailable.
CONCLUSION
We have identified a potential role for PI3k in accelerated metastatic tumor growth following laparotomy. In so doing, we have partly characterized the intracellular events that underpin this phenomenon. Given the differential effects of laparotomy and laparoscopy on recurrent tumor growth, it is now important to characterize the benefits of targeting PI3 kinase in animal models of perioperative tumor growth following laparoscopy. Finally, we have identified a potential strategy for protection against accelerated metastatic tumor growth during that important therapeutic window, ie, the postoperative interval.
